Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA .2. Modification of pyrrolidine ring at P1' proline

被引:16
作者
Komai, T
Higashida, S
Sakurai, M
Nitta, T
Kasuya, A
Miyamaoto, S
Yagi, R
Ozawa, Y
Handa, H
Mohri, H
Yasuoka, A
Oka, S
Nishigaki, T
Kimura, S
Shimada, K
Yabe, Y
机构
[1] SANKYO CO LTD,BIOL RES LABS,SHINAGAWA KU,TOKYO 140,JAPAN
[2] SANKYO CO LTD,EXPLORATORY CHEM RES LAB,SHINAGAWA KU,TOKYO 140,JAPAN
[3] TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN
[4] UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN
关键词
D O I
10.1016/0968-0896(96)00130-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Systematic replacement in the 3- or 4-position of the pyrrolidine ring at P1' proline was carried out. Compound 26, which has a C1 atom in the 4(S)-position was the most active among inhibitors substituted with other halogen atoms or other substituents. Furthermore, the replacement of the Z group in compound 26 with five- or six-membered fused aromatic heterocycle carbonyl groups produced more potent inhibitors. 7-Methoxybenzofuran-2-carbonyl derivative (44) was the best of these and showed K-i = 4.5 nM against HIV PR and IC(50)s 0.58 mu M and 0.06 mu M in chronic and acute infections, respectively. These results suggest that the combination of the 4(S)-Cl atom and fused bicyclic heterocycles may be effective in improving their cellular penetration. Copyright (C) 1996 Elsevier Science Ltd
引用
收藏
页码:1365 / 1377
页数:13
相关论文
共 18 条
[1]  
BERNSTEIN FC, 1987, CRYSTALLOGRAPHIC DAT, P107
[2]   CHARMM - A PROGRAM FOR MACROMOLECULAR ENERGY, MINIMIZATION, AND DYNAMICS CALCULATIONS [J].
BROOKS, BR ;
BRUCCOLERI, RE ;
OLAFSON, BD ;
STATES, DJ ;
SWAMINATHAN, S ;
KARPLUS, M .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1983, 4 (02) :187-217
[3]   THE HIV-1 PROTEASE AS A THERAPEUTIC TARGET FOR AIDS [J].
DEBOUCK, C .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (02) :153-164
[4]  
EWING WR, 1988, HETEROCYCLES, V27, P2843
[5]   QUANTITATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 IN THE BLOOD OF INFECTED PERSONS [J].
HO, DD ;
MOUDGIL, T ;
ALAM, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (24) :1621-1625
[6]   ACTIVE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE IS REQUIRED FOR VIRAL INFECTIVITY [J].
KOHL, NE ;
EMINI, EA ;
SCHLEIF, WA ;
DAVIS, LJ ;
HEIMBACH, JC ;
DIXON, RAF ;
SCOLNICK, EM ;
SIGAL, IS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4686-4690
[7]  
KOMAI T, UNPUB J ANTIBIOT
[8]   HTLV-III GAG PROTEIN IS PROCESSED IN YEAST-CELLS BY THE VIRUS POL-PROTEASE [J].
KRAMER, RA ;
SCHABER, MD ;
SKALKA, AM ;
GANGULY, K ;
WONGSTAAL, F ;
REDDY, EP .
SCIENCE, 1986, 231 (4745) :1580-1584
[9]   RECENT ADVANCES IN THE DESIGN OF HIV PROTEINASE-INHIBITORS [J].
MARTIN, JA .
ANTIVIRAL RESEARCH, 1992, 17 (04) :265-278
[10]   STRUCTURE OF COMPLEX OF SYNTHETIC HIV-1 PROTEASE WITH A SUBSTRATE-BASED INHIBITOR AT 2.3-A RESOLUTION [J].
MILLER, M ;
SCHNEIDER, J ;
SATHYANARAYANA, BK ;
TOTH, MV ;
MARSHALL, GR ;
CLAWSON, L ;
SELK, L ;
KENT, SBH ;
WLODAWER, A .
SCIENCE, 1989, 246 (4934) :1149-1152